Volume 6.46 | Nov 27

Mammary Cell News 6.46 November 27, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
Researchers Identify New Ways to Drain Cancer’s ‘Fuel Tank’
By observing cancer stem cells in a lab setting, researchers discovered that mitochondria are especially important for the proliferative expansion and survival of cancer stem cells, also known as ‘tumor initiating cells’, which would then promote treatment resistance. The research was carried out in breast cancer stem cells grown in a lab, but the theory was also checked against human breast cancer cells from patients. [Research from the University of Manchester discussing publication in Oncotarget] Press Release | Full Article
Culture and Characterize Mouse Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Mouse) Free Protocols
PUBLICATIONS (Ranked by impact factor of the journal)

MACROD2 Overexpression Mediates Estrogen Independent Growth and Tamoxifen Resistance in Breast Cancers
Researchers found MACROD2 is amplified and overexpressed in metastatic tamoxifen-resistant tumors. Transgene overexpression of MACROD2 in breast cancer cell lines results in tamoxifen resistance, whereas RNAi-mediated gene knock down reverses this phenotype. [Proc Natl Acad Sci USA] Abstract | Press Release

A Positive Role of DBC1 in PEA3-Mediated Progression of Estrogen Receptor-Negative Breast Cancer
Scientists report that deleted in breast cancer 1 (DBC1) functions as a coactivator for the oncogenic ETS transcription factor PEA3 to promote estrogen receptor (ER)-negative breast cancer progression. DBC1 depletion inhibited the tumorigenic properties of ER-negative breast cancer cells in vitro and in vivo. [Oncogene] Abstract

Invasive Breast Carcinoma Cells from Patients Exhibit MenaINV– and Macrophage-Dependent Transendothelial Migration
Scientists found that intravasation of breast cancer cells may be prevented by blocking the signaling between cancer cells and macrophages. They obtained invasive breast ductal carcinoma cells of various subtypes by fine-needle aspiration biopsies from patients and found that, in an in vitro transendothelial migration assay, cells that migrated through a layer of human endothelial cells were enriched for the transcript encoding MenaINV. [Sci Signal] Abstract | Press Release

Combination Therapy Targeting Ectopic ATP Synthase and 26S Proteasome Induces ER Stress in Breast Cancer Cells
Researchers investigated the anticancer effects of the ATP synthase inhibitor citreoviridin on breast cancer cells through proteomic approaches and revealed that differentially expressed proteins in cell cycle regulation and in the unfolded protein response were functionally enriched. [Cell Death Dis] Full Article

Inhibition of SGK1 Enhances mAR-Induced Apoptosis in MCF-7 Breast Cancer Cells
Testosterone albumin conjugates (TAC)-stimulated membrane androgen receptors (mAR) activation elicited apoptosis of MCF-7 cells, an effect significantly potentiated by concomitant incubation of the cells with TAC and the specific SGK1 inhibitors EMD638683 and GSK650394. [Cancer Biol Ther] Abstract

Tumor Necrosis Factor-α Sensitizes Breast Cancer Cells to Natural Products with Proteasome-Inhibitory Activity Leading to Apoptosis
Tumor necrosis factor-α, when combined with withaferin A or celastrol, activated caspase-3 and -9 and downregulated XIAP in a dose-dependent manner, leading to induction of apoptosis in MDA-MB-231 breast cancer cells. [PLoS One] Full Article

The Cytotoxic Effect of the NOS-Mediated Oxidative Stress in MCF-7 Cells after PbCl2 Exposure
Scientists show that PbCl2 treatment depresses the expressions of the three distinct nitric oxide synthase (NOS) isoforms: neuronal nitric oxide synthase, endothelial NOS, and inducible NOS on both transcriptional and translational levels in MCF-7 cells. [Environ Toxicol] Abstract

Kisspeptin-10 Inhibits the Migration of Breast Cancer Cells by Regulating Epithelial-Mesenchymal Transition
Researchers demonstrate the antitumor effects of kisspeptin-10 (KP-10) on human breast cancer cell lines, MDA-MB-231 and MDA-MB-157, both in vitro and in vivo. KP-10 was observed to induce apoptosis and inhibit the mobility of MDA-MB-231 and MDA-MB-157 cells. [Oncol Rep] Abstract

Docetaxel Modulates the Delayed Rectifier Potassium Current (IK) and ATP-Sensitive Potassium Current (IKATP) in Human Breast Cancer Cells
Scientists investigated the effects of docetaxel on the IK and the IKATP in two human breast cancer cell lines, MCF-7 and MDA-MB-435S, using the whole-cell patch-clamp technique. They show that docetaxel inhibited the IK and IKATP in both cell lines in a dose-dependent manner. [J Membr Biol] Abstract


SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
Scientists determined the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. [J Clin Oncol] Abstract

Clinical Significance of SPRR1A Expression in Progesterone Receptor-Positive Breast Cancer
Researchers focused on the expression of small proline-rich repeat protein 1A (SPRR1A) protein in breast cancers (BCs) in China. The relationship between SPRR1A expression and clinicopathological factors as well as BC prognoses was also determined. [Tumor Biol] Abstract

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
Animal Models for Exploring the Pharmacokinetics of Breast Cancer Therapies
This review focuses on transgenic, xenograft, and syngeneic murine breast cancer models, the ectopic, orthotopic and intravenous methods of cell implantation, and the ethics of animal experimentation. It also includes the latest data on tumor gene expression and the issues to consider when exploring the pharmacokinetics and efficacy of breast cancer therapies. [Expert Opin Drug Metab Toxicol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Synthon Initiates Treatment of First Patients in Phase I Trial of Anti-HER2 ADC SYD985 Based on Its Proprietary Linker-Drug Platform
Synthon Biopharmaceuticals announced that the first patients with metastatic solid tumors have commenced treatment with its investigational anti-HER2 antibody-drug conjugate (ADC), SYD985. [Synthon Biopharmaceuticals] Press Release

Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (Nivolumab) and FPA008 in Six Tumor Types
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo, Bristol-Myers Squibb’s investigational programmed death-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor. [Bristol-Myers Squibb Company] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposium – PI 3-Kinase Signaling Pathways in Disease
January 13-18, 2015
Vancouver, Canada

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Position – Molecular Mechanisms of Differentiation and Oncogenesis (University of Massachusetts Medical School)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Associate Professor – Physiology (University of Bergen)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Professor – Breast/Abdominal Surgery or Gynecology (Fudan University Shanghai Cancer Center)

Postdoctoral Position – Protein-Protein Interactions in Leukemia and Breast Cancer (University of Dundee)

PhD Position – Protein Interactions in Cancer Regulation (University of East Anglia)

Postdoctoral Fellow – Breast Cancer (University of Texas Health Science Center at San Antonio)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us